Channels - Short-Term Intraocular Pressure Changes After Intravitreal Aflibercept 8 mg via Prefilled Syringe :: FRELIP Discovery

Similar Items: Short-Term Intraocular Pressure Changes After Intravitreal Aflibercept 8 mg via Prefilled Syringe

Quick Look
Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg: A 96-Week Pooled Analysis from PULSAR and PHOTON
Quick Look
Safety of GBL1204—An Ophthalmic Bevacizumab in Prefilled Syringe for Neovascular Age-Related Macular Degeneration: A Phase I Study
Quick Look
Advances in Polypoidal Choroidal Vasculopathy (PCV) Management: Emerging Evidence for Faricimab and Aflibercept 8 mg
Quick Look
Functional Real-World Outcomes of Aflibercept 8 mg Versus Faricimab After Loading Phase in Diabetic Macular Edema
Quick Look
Prospective Real-World Outcomes After Switching to Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration with High Treatment Burden
Quick Look
Visual Gains with Faricimab vs Aflibercept 8 mg in Naïve Retinovascular Disease: Global Real-World Cases and Literature Review
Quick Look
Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US
Quick Look
Macular Neovascular Membrane as a Late Complication of Acute Posterior Multifocal Placoid Pigment Epitheliopathy (APMPPE) Managed With Intravitreal Aflibercept
Quick Look
Summary of Research: Aflibercept 8 mg versus Faricimab Treat‑and‑Extend for Diabetic Macular Edema or Neovascular Age‑Related Macular Degeneration: A Bayesian Fixed‑Effect Network Meta‑analysis of Clinical Trials
Quick Look
Letter to the Editor Regarding “Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials”
Quick Look
Near Fixation–Associated Intraocular Pressure Reduction in Intermittent Exotropia: Postoperative Changes After Strabismus Surgery
Quick Look
A Response to: Letter to the Editor Regarding “Aflibercept 8 mg Versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials”
Quick Look
Systemic and ocular complications related to intravitreal administration of anti-VEGF agents
Quick Look
Posture-Induced Intraocular Pressure Changes at Different Times of Day in Primary Open-Angle Glaucoma: Associated Factors and Exploratory Analyses of Antiglaucoma Medication Regimens
Quick Look
Intravitreal Faricimab for Retinal Vein Occlusion: Real-World Outcomes from the Multicenter FARTURK-RVO Study in Türkiye
Quick Look
Efficacy and Safety Outcomes of Fluocinolone Acetonide Intravitreal Implant in Refractory Diabetic Macular Edema: A Real-World Study
Quick Look
Segmentation Errors of Two Modern Biometers in 100 Eyes with Phakic Intraocular Lenses
Quick Look
Supine and Sitting Intraocular Pressure Measurements Using iCare HOME2 Self-Tonometry and iCare IC200 Rebound Tonometry in Japanese Open-Angle Glaucoma Patients
Quick Look
Clinical Outcomes of Neovascular Glaucoma in Patients with Prior and Non-Prior Intravitreal Anti-VEGF Treatment: A Retrospective Cohort Study
Quick Look
Exposure to and Comfort with Toric and Presbyopia-Correcting Intraocular Lenses: A Survey of Ophthalmology Residents
Quick Look
Real-Life 1-Year Results and Predictors of Visual Outcome with Intravitreal Faricimab for Treatment of Exudative Neovascular Age-Related Macular Degeneration
Quick Look
Potential Refractive Error Due to Axial Displacement of Intraocular Lenses with Clinically Relevant Compression Diameters
Quick Look
Real-World Utilization and Initial Experience with Aflibercept-ayyh (PAVBLU) for Retinal Disorders in United States Retina Practices: A Descriptive Retrospective Analysis
Quick Look
Aflibercept 24-Month Outcomes in Diabetic Macular Edema With and Without Prior Macular Laser Therapy: Data from the Fight Retinal Blindness! Registry